Kelun-Biotech’s Investigational New Drug (IND) application for SKB105 (CR-003), an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumours. In December 2025, Kelun-Biotech and Crescent Biopharma entered a strategic collaboration for SKB105/CR-003 […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!